Aurobindo Pharma Limited (NSE:AUROPHARMA) Q4 FY23 Earnings Concall dated May. 28, 2023. Corporate Participants: Deepti Thakur -- Investor Relations & Corporate Communications
Aurobindo Pharma Limited (AUROPHARMA) Q4 FY23 Earnings Concall Transcript

Aurobindo Pharma Limited (NSE:AUROPHARMA) Q4 FY23 Earnings Concall dated May. 28, 2023. Corporate Participants: Deepti Thakur -- Investor Relations & Corporate Communications
Shalby Ltd.‘s revenues in Q3FY23 rose 25% to ₹ 2,067 millions. Consolidated Profit After Tax came at ₹ 153 millions showcasing an
https://www.youtube.com/watch?v=ECd3N-qiOMo Key highlights from Prevest Denpro Limited (PREVEST) Q3 FY22 Earnings Concall Q&A Highlights: Pranay Jain from Dealwell Capital asked that since
Dr. Reddy's Laboratories (NSE:DRREDDY) Q3 FY22 Earnings Concall dated Jan. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations Parag
The pharma giant Cipla (NSE: CIPL) reported its second-quarter 20223 earnings results on Tuesday after market hours. The total revenue increased by
The Indian pharmaceutical industry is the world’s third-largest by volume and 14th largest by value. The turnover of the country’s pharmaceutical market
Healthcare is amongst the fastest-growing sectors in India, both in terms of revenue and employment. The Indian healthcare industry is expected to
Aurobindo Pharma Ltd (NSE:AUROPHARMA) Q3 FY21 earnings concall dated Feb. 10, 2021. Corporate Participants: Krishna Kiran -- Manager of Investor Relations Santhanam
Dr.Reddy's Laboratories Ltd (NSE: DRREDDY) Q3 FY21 earnings Concall dated Jan. 29, 2021. Corporate Participants: Amit Agarwal -- Head of Investor Relations